Bank Of New York Mellon Corp Nkarta, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.14 - $14.35 $542,120 - $1.51 Million	105,471 New	105,471 $631,000
Q3 2022 Nov 14, 2022	SELL	$12.27 - $18.39 $365,228 - $547,396	-29,766 Reduced 22.05%	105,241 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$7.77 - $19.44 $628,608 - $1.57 Million	80,902 Added 149.53%	135,007 $1.66 Million
Q1 2022 May 11, 2022	SELL	$8.66 - $14.99 $4,355 - $7,539	-503 Reduced 0.92%	54,105 $615,000
Q4 2021 Feb 11, 2022	BUY	$12.79 - $26.88 $4,745 - $9,972	371 Added 0.68%	54,608 $838,000
Q3 2021 Nov 12, 2021	BUY	$26.67 - $38.76 $61,100 - $88,799	2,291 Added 4.41%	54,237 $1.51 Million
Q2 2021 Aug 11, 2021	SELL	$23.94 - $36.68 $312,129 - $478,233	-13,038 Reduced 20.06%	51,946 $1.65 Million
Q1 2021 May 13, 2021	BUY	$31.33 - $59.61 $141,329 - $268,900	4,511 Added 7.46%	64,984 $2.14 Million
Q4 2020 Feb 09, 2021	BUY	$27.03 - $75.62 $352,957 - $987,445	13,058 Added 27.54%	60,473 $3.72 Million
Q3 2020 Nov 12, 2020	BUY	$23.52 - $47.9 $1.12 Million - $2.27 Million	47,415 New	47,415 $1.43 Million

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.